Brief: In8bio's Deltex Gamma-Delta T Cells Show Promise In Targeting Ovarian Cancer
Brief: IN8bio Reports First Quarter 2023 Financial Results
Brief: IN8BIO Says On May 1, Board Of Co Increased Size Of Board To Seven From Six Directors
Brief: In8bio Appoints Jeremy Graff To Board Of Directors
Brief: IN8BIO May Offer Shares Of Common Stock Of Up To $5.9 Mln Under Sales Agreement
Brief: In8bio Receives FDA Orphan Drug Designation For Inb-400/410 For The Treatment Of Newly Diagnosed Glioblastoma
IN8bio jumps on positive results from early-stage leukemia trial
Brief: In8bio Presents Positive, New Inb-100 Data Showing Long-Term Complete Remissions And Elevated Gamma-Delta T Cells In 100% Of Evaluable Treated Leukemia Patients At Ebmt 2023
Brief: In8bio Announces Positive Preclinical Data For Gamma-Delta Car Platform And Launches New Cd33 Program At AACR Annual Meeting 2023
Brief: IN8bio Reports Fourth Quarter And Full-Year 2022 Financial Results And Provides Corporate Update
Brief: In8bio Confirms It Does Not Hold Any Deposits At Silicon Valley Bank
Brief: IN8bio Provides INB-200 Clinical Update And Outlines 2023 Pipeline Goals
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
Brief: In8bio Announces Positive Data In Early-Stage Trial Of Blood Cancer Treatment
IN8bio rises on positive data in treatment trial of blood cancers
Brief: In8bio Announces FDA Clearance To Initiate Phase 2 Clinical Trial Of INB-400 For Glioblastoma
Brief: In8bio Partners With The Dunbar Car T-Cell Program At University Of Louisville
U.S. STOCKS ON THE MOVE-Best Buy, Mosaic, Getty Images, Big Lots
U.S. STOCKS ON THE MOVE-Arbutus, Trimble, Hempacco